Role of B-type natriuretic peptide in cardiovascular state monitoring in a hemodialysis patient with primary amyloidosis.
BACKGROUND
Cardiac involvement occurs in up to 50% of patients with primary or A amyloidosis (ALA) and is associated with very poor prognosis. B-type natriuretic peptide (BNP) has been proposed as a guide for treatment of heart failure patients and as an index of myocardial dysfunction in patients with ALA. Data about BNP dosage for cardiovascular monitoring of patients with ALA on renal replacement therapy are lacking.


METHODS
A 64 year old Caucasian man was admitted because of nephrotic syndrome in July 2003. Renal diagnosis was ALA. Melphalan and prednisolone were given but renal function worsened and in April 2004 standard bicarbonate hemodialysis was started. In March 2004 thalidomide was added to his therapy. During the follow-up ejection fraction was stable and was 65% on the contrary E/A ratio gradually increased and overtook 1. BNP plasma levels were increased and the values recorded during the follow-up were: 2505 pg/mL in October 2003 (normal reference values<100), 1827 in April 2004, 4006 in June 2004, 5000 in September 2004, 3750 in January 2005 and 1920 in April 2005. In September 2005 BNP was 3380 pg/mL. The patient was still alive after a follow-up longer than two years.


CONCLUSIONS
In ALA patients a powerful prognostic role of BNP has been reported whose expression is increased in ventricular myocytes of patients with cardiac involvement. BNP level monitoring does not appear to be superior to standard echocardiography in evaluating cardiovascular status of uremic patients with ALA.
Fabbian
F
F
Renal Unit, St. Anna Hospital, Ferrara, Italy. f.fabbian@ospfe.it
Stabellini
N
N
Sartori
S
S
Molino
C
C
Russo
G
G
Russo
M
M
Cantelli
S
S
Catizone
L
L
D000686:Amyloidosis / Q000150:complications*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001639:Bicarbonates / Q000627:therapeutic use; D002021:Buffers; D002303:Cardiac Output, Low / Q000097:blood* / Q000503:physiopathology; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000150:complications*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D009404:Nephrotic Syndrome / Q000209:etiology; D011239:Prednisolone / Q000627:therapeutic use; D006435:Renal Dialysis; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D001639:Bicarbonates; D002021:Buffers; D007166:Immunosuppressive Agents; D020097:Natriuretic Peptide, Brain; D013792:Thalidomide; D011239:Prednisolone; D008558:Melphalan